Murine lymphoid cells were infected in vitro with purified leukemogenic radiation leukemia virus (RadLV) produced by virus-induced lymphoblast cell lines. Thymocytes were shown to be highly susceptible to infection by the virus, whereas murine or other fibroblasts were refractory to it. Murine bone marrow and spleen cells were shown to be much less sensitive to infection by this thymotropic RadLV. By comparison, a B-tropic RadLV isolate (RadLV*), propagated on a mouse fibroblast cell line, was noninfectious for lymphoid cells but infected fibroblasts. A correlation was shown to exist between in vitro infection of thymocytes, as assayed by immunofluorescence, and in vivo leukemogenicity of the thymotropic RadLV. This constitutes a rapid in vitro test for in vivo leukemogenicity of a natural lymphatic leukemia virus.
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The endogenous RNA C-type viruses that occur in vivo in C57BL/6 (B6) mice after exposure to physical agents (1) are clearly linked etiologically to the lymphatic leukemias induced in these mice. These viruses, collectively designated radiation leukemia virus (RadLV), have been propagated in vivo (2) . They can be consistently extracted from tumors that have been induced by virus injection, and to a lesser extent from tumors induced by x-irradiation (1, 3). Recent biochemical and genetic evidence has shown that multiple biologically distinguishable C-type viruses are naturally present within the cells of many mouse strains (4, 5) . Thus (6) have induced RNA C-type viruses in cell culture fibroblasts which were shown to be leukemogenic in vivo. Haas has shown (7) that a purified C-type cell-culture-derived virus originally induced by x-rays in B6 mice is leukemogenic in its original host.
A problem that has hampered progress in murine leukemia virus (MuLV) research involves the decreased leukemogenicity of many murine leukemia viruses after their passage through cultures of mouse embryo fibroblasts (MEF). Long-term passage of MuLV through mouse embryo fibroblasts usually results in the production of "attenuated" virus that has lost most or all of its pathogenic properties; this has been shown to be true for the Friend (8) (9) (10) and Rauscher (10) (11) (12) cently also for the natural lymphatic leukemia-inducing Gross-AKR (10, 13, 14) and the radiation leukemia (RadLV) (15) variants of MuLV. In contrast to the loss of oncogenicity of MEF-grown virus, long-term in vitro culture of MuLV has consistently produced potent in vivo leukemogenic viruses whenever the virus was cultered in or produced by cells of lymphatic origin (7, 16, 17) .
Studies from a number of laboratories have amply demonstrated that both Friend MuLV and Rauscher MuLV (18) are composed of two viral entities with quite different biological properties. The two components together cause the induction of the classical erythroblastic disease pattern described by Friend (19) . These virus complexes are composed of a replicating lymphatic leukemia virus (LLV) (20) and a "defective" spleen focus forming virus (SFFV). The two entities have been studied separately by a variety of biological methods, and loss of the "defective" virions is responsible for attenuation of these virus complexes when passaged through mouse fibroblast cultures (see ref. 21 for a comprehensive review). It has not been possible so far to obtain the "defective" SFFV particles free of the helper LLV, so that one could not test whether the "defective" virions have by themselves pathogenic properties, as is seen in combination with the helper LLV.
The Viruses. Included was the thymotropic virus 136-4, a RadLV produced in tissue culture from a continuous line of B6 RadLV-induced thymoma (7). The virus was concentrated and purified through two sequential bandings in continuous sucrose gradients and had a % IFC titer of 6 X 107 per 0.4 ml when assayed by the % IFC assay of Decleve et al. (27) on B6 thymocytes. K127, a similar thymotropic virus, was produced by a continuous rat lymphoma cell line K127R, originally induced in vivo by injection of P127 RadLV. This virus had a titer of 2 X 108/0.4 ml by the % IFC assay on B6 thymocytes. RadLV*, in vitro passaged RadLV, was harvested from the supernatant fluid of 3-dayold BL5 (RadLV) cell cultures (titer 3 X 107/0.4 ml) (15) . GLV*, in vitro passaged Gross leukemia virus, was harvested from the supernatant fluids of 3-day-old C3H (GLV) cell cultures. The last two virus preparations were kindly supplied by Dr. A. Decleve. Passage 127 (P127) and passage 136 (P136) are preparations of RadLV prepared as cell-free extracts of RadLV-induced B6 mouse lymphoma tissue, as described (28) .
Infection Procedure was the D-P procedure described by Decleve et al. (27) , which involves a 1-hr treatment of the cells with 25 gg/ml of DEAE-dextran in modified Eagle's medium containing 1% serum, followed by infection with 0.4 ml of virus diluted in the same medium containing 4 ,gg/ml of polybrene (Aldrich Chemical Co. XC Plaque Assays were used as described (31, 32) , and a reverse XC plaque procedure was used (33) . The XC cell line was kindly supplied through the courtesy of Dr. A. Hackett, and showed no spontaneous syncytium formation.
RESULTS
Infection of fibroblast cell cultures with the thymotropic RadLV and control virus RadLV* Infection of fibroblast cells was followed by the appearance of virus-related antigens in the cytoplasm of 11 Table 4 shows that a correlation (14, 15) . On the other hand, upon passage of GLV through susceptible cells of lymphoid origin (16, 17) or production of RadLV in similar cells (7) , the virus retains in vivo leukemogenicity, while virus infectivity on fibroblast cells is completely lost, as is shown here. The data presented in this paper therefore show that in vitro thymocyte passage of RadLV selects a thymotropic, leukemogenic virus that has little predisposition for growth on murine or other fibroblasts. Two possible interpretations may account for this selection phenomenon. One is that in vitro passage of natural RadLV, which has been shown to be leukemogenic (41) and thymotropic (t, 43, 44) , is initially capable of replication on fibroblasts (15) , though perhaps with some difficulty (42) . Selective passage on fibroblast cultures would tend to select variants that grow better on fibroblasts (RadLV*) but that have lost their leukemogenicity and thymotropism, whereas converse passage on thymocytes tends to select variants that may have lost their capacity to grow on fibroblasts (i.e., the thymotropic RadLV under discussion), but retain leukemogenicity and thymotropism. A second hypothesis is also entirely plausible. According to this alternative hypothesis, natural in vivo RadLV would be composed of a heterologous mixture of two different viruses, a thymotropic agent and a virus capable of infecting fibroblasts only. Propagation of the natural virus on either cell type would favor selection of only one of the two virus components. The loss of either agent would accentuate the particular properties of the remaining, propagated virus.
The data presented here do not distinguish between these two possible interpretations. Natural tumor-derived RadLV is thymotropic in vivo (43, 44) , and the in vitro derived thymotropic RadLV 136.4 is thymotropic in viot and in vitro (this paper). It seems therefore plausible that the thymotropic RadLV represents the transforming vector whereas the B-tropic RadLV*, which is sometimes present in radiationinduced thymomas, is either a passenger virus or performs a hitherto unknown function in leukemia induction. By analogy, some support for this interpretation comes from the lymphotropism of the Abelson murine leukemia virus, with 
